Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Takeda Oncology.

Advances In™: European Perspectives on the Evolving Role of CD30+ in Treatment of HL, PTCL, and CTCL

Release Date: March 15, 2021
Expiration Date: March 15, 2022

Activity Overview

Overexpression of CD30 in Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphomas (CTCL) have led to the exploration of CD30 as a therapeutic target in these cancers. Testing for CD30 expression is important in the differential diagnosis of these malignancies and helps to individualize therapy.

Recent advances in antibody engineering have paved the way for new applications of CD30-directed therapies, including the development of novel immunotherapeutic agents called antibody-drug conjugates (ADCs). CD30-targeted therapies such as brentuximab vedotin are approved in some lymphomas, and clinical trials of CD30-directed therapies are ongoing.

This program is aimed at providing oncology clinicians with global expert perspectives on the role of CD30 in patients with HL, PTCL, and CTCL. The essentials of disease diagnosis, staging, molecular testing, current and emerging CD30-directed therapies, and management of treatment-related toxicities will be presented in a multimedia format that includes a series of video interviews with two expert thought leaders integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is intended for a global audience of medical oncologists, hematologists, pathologists, and hematopathologists interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, dermatologic oncologists, dermatologists, and other health care professionals interested in the treatment of patients with hematologic malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss the role of CD30 and rationale for its testing for individualizing treatment decisions in patients with Hodgkin lymphoma (HL), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphomas (CTCL)
  • Review efficacy and safety data for CD30-targeted agents for the treatment of patients with HL, PTCL, and CTCL
  • Plan strategies for proactively recognizing, monitoring, and managing adverse events associated with CD30-targeted treatment of patients with HL, PTCL, and CTCL in the front-line setting and beyond
  • Review emerging novel therapies and the latest clinical trial data for CD30-targeted therapies for the treatment of patients with HL, PTCL, and CTCL

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Andreas Engert, MD
Andreas Engert, MD
Professor of Internal Medicine, Hematology, and Oncology
Department of Internal Medicine
Chairman, German Hodgkin Study Group
University Hospital of Cologne
Cologne, Germany

Disclosures: Grant/Research Support: Bristol Myers Squibb, Takeda; Consultant: Takeda, Tessa Therapeutics; Other (Lecture Fees): AstraZeneca, Hexal, Innovent, Janssen.

Emanuele Zucca, MD
Emanuele Zucca, MD
Scientific and Medical Director
International Extranodal Lymphoma Study Group
Foundation for the Institute of Oncology Research
Ospedale Regionale di Bellinzona e Valli
Deputy Head
Clinic of Medical Oncology
Oncology Institute of Southern Switzerland
Ente Ospedaliero Cantonale
Faculty of Biomedical Sciences
Università della Svizzera Italiana
Bellinzona, Switzerland

Disclosures: Grant/Research Support: AstraZeneca, Celgene, Janssen, Roche; Consultant (Advisory Board): BeiGene, Incyte, Janssen, Merck, Roche; Other (Travel Grant): Roche.

Physicians’ Education Resource®, LLC (PER®), uses a blinded peer-review process. The peer reviewer discloses the following:

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By